Navigation Links
InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe
Date:12/17/2010

e conference ID# 33188579.  The webcast will remain available on the company's website until the next earnings call.

About Esbriet (pirfenidone)

Preclinical and in-vitro evidence has shown that Esbriet has both anti-fibrotic and anti-inflammatory effects.  In February 2009, InterMune announced the results of the company's two pivotal Phase 3 clinical trials evaluating Esbriet for the treatment of IPF, known as the CAPACITY trials.  In clinical studies, Esbriet was safe and generally well-tolerated, with the most frequent side effects reported being photosensitivity rash and gastrointestinal symptoms.  Since 2008, pirfenidone has been marketed in Japan as Pirespa® by Shionogi & Co. Ltd.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology.  InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections.  The pulmonology portfolio includes Esbriet™ (pirfenidone) for which InterMune has completed a Phase 3 program in patients with IPF (CAPACITY).  The Marketing Authorization Application (MAA) for Esbriet received a positive CHMP opinion that is now awaiting ratification by the European Commission.  The hepatology portfolio includes next-generation HCV protease inhibitor and NS5A research programs.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to the anticipated receipt
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. InterMune to Release Third Quarter Financial Results on October 28
2. InterMune Sells Danoprevir Rights to Roche for $175 Million
3. InterMune to Present at 2010 Citi Health Care Conference
4. InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
5. InterMune to Release First Quarter Financial Results on April 29
6. InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF
7. InterMune Announces Proposed Public Offering of Common Stock
8. InterMune to Release Third Quarter Financial Results on November 5
9. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
10. InterMune to Present at Canaccord Adams Conference
11. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... DC (PRWEB) January 14, 2014 Carahsoft ... for Thursday, January 23, 2014 at 2pm EST (11am ... Knowledge.” The topic focuses on how technology can turn ... critical decisions for government agencies. The online webinar will ...
(Date:1/14/2014)... 14, 2014  3D Communications, a leading provider of strategic communications services ... media events in the United States and ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as Associate ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... Oct. 24, 2011 Marshall Edwards, Inc. (Nasdaq: ... of novel therapeutics targeting cancer metabolism, announced today that Charles ... Company, has been appointed to its board of directors. The ... to six and the number of independent directors to five. ...
... (NYSE symbol: OME), a nutritional ingredient company and the ... fish meal products, today announced that it has retained ... with its omega-3 fish oil and omega-3 concentrate research ... analytical services and biotechnology consulting company that specializes in ...
... Oct. 24, 2011 Heart repair.  Bone repair. ...  Cerebral Palsy.  Diabetes.  Alzheimer,s.  Cystic Fibrosis.  Leukemia, Sickle ... metabolic disorders. "These diseases or group ... cured with umbilical cord blood stem cells or ...
Cached Biology Technology:Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors 2Marshall Edwards Appoints Healthcare Investment Banking Veteran Charles Baltic to Board of Directors 3Omega Protein Announces Retention of Lipid Technologies, LLC 2Cord Blood America Provides Insight on Worldwide Research Using Umbilical Cord Blood Stem Cells to Treat Numerous Diseases 2Cord Blood America Provides Insight on Worldwide Research Using Umbilical Cord Blood Stem Cells to Treat Numerous Diseases 3
(Date:4/22/2014)... club of a mantis shrimp, a team of researchers ... University of Southern California and Purdue University, have developed ... impact resistant and tougher than the standard used in ... this tiny crustacean, the more we realize its structure ... said David Kisailus, a Kavli Fellow of the National ...
(Date:4/22/2014)... Biology (FASEB) has released updated factsheets for ... National Institutes of Health (NIH) benefits each of the ... to make these factsheets available to help citizens and ... said FASEB President, Margaret K. Offermann, MD, PhD. NIH ... funding, investing $29.2 billion in FY 2013 in medical ...
(Date:4/22/2014)... begins a trip to Asia to coordinate with ... Pacific, officials at the Office of Naval Research ... Partnership (APTEP) as an example of strong and ... allies in the region. , The APTEP program, ... region, supports the development of alternative energy technologies. ...
Breaking Biology News(10 mins):Mantis shrimp stronger than airplanes 2Mantis shrimp stronger than airplanes 3Full power: Alternative energy partnerships flourish in Asia 2Full power: Alternative energy partnerships flourish in Asia 3
... CREEK, CAMessages from nearly a half-billion years ago, conveyed ... moss, provide clues about the earliest colonization of dry ... Joint Genome Institute (DOE JGI) was among the leaders ... to complete the first genome sequencing project of a ...
... published a paper today that is the most comprehensive ... are having on the worlds coral reefs. The ... and Ocean Acidification, co-authored by seventeen marine scientists from ... not survive the drastic increases in global temperatures and ...
... The Stowers Institutes Rong Li Lab, in collaboration ... quantitative in vivo measurement of the dynamic protein-protein ... signaling pathway, which is critical to growth and ... paper, Mapping Dynamic Protein Interactions in the MAP ...
Cached Biology News:DOE JGI Community Sequencing Program delivers first moss genome 2DOE JGI Community Sequencing Program delivers first moss genome 3Immediate action needed to save corals from climate change 2Immediate action needed to save corals from climate change 3Rong Li Lab reports protein interactions of MAP kinase signaling pathway 2
Physical Form: powder Color: white Removes FLAG peptide from N-terminal and Met-N-terminal fusion proteins. Supplied with optimized enterokinase buffer....
This antibody detects ubiquitinated proteins on SDS-PAGE immunoblots. It does not detect free ubiquitin....
... The Jouan B4i ventilated and BR4i refrigerated multifunction ... low speed operation at a low sound level ... certified for biocontainment. Their AUTO-LOCK rotor exchange system ... ready for use within seconds. Instant ...
... BR4i refrigerated multifunction centrifuges are equally capable of ... low sound level with a large range of ... rotor exchange system without tools ensures that the ... Instant rotor exchange (5 sec.) ...
Biology Products: